Estradiol vs. Estriol vs. Estrone: Understanding the Three Major Estrogens

The three estrogens, at a glance

"Estrogen" is not one molecule. The human body produces three principal estrogens — estrone (E1), estradiol (E2), and estriol (E3) — and they differ meaningfully in where they come from, how strongly they act on estrogen receptors, and when in life they predominate. Patient materials and even some clinical conversations sometimes use "estrogen" as if it were a single substance with a single dose and a single risk profile. It isn't, and that distinction matters for anyone trying to understand a compounded hormone prescription.

The table above reflects the general, widely-taught relative ordering of estrogen receptor activity. It is a simplification — actual biological effect depends on receptor subtype, tissue, dose, and duration of exposure, not just a single potency ranking.

Relative biological activity

Estrogen receptor activity is usually discussed in terms of binding affinity and downstream transcriptional effect at estrogen receptors alpha and beta. Estradiol is consistently described as the most potent of the three at the receptor level overall, which is why it is the reference compound most systemic hormone therapy research is built around. A 2017 comparative pharmacology study measuring precise equilibrium dissociation constants found that estradiol and estriol displayed similar binding affinities to their respective reference standards, while estrone specifically showed lower binding affinity at estrogen receptor beta (ERβ). On one endogenous estrogen-responsive gene promoter tested in that study, estradiol and estriol were equally potent and efficacious, while estrone was less potent and less efficacious than estradiol.^[1] The overall picture is more nuanced than a single "most potent to least potent" ranking: differences vary by receptor subtype and by which cellular response is being measured, not by a fixed hierarchy that applies identically everywhere.

Where each estrogen comes from

Estradiol is produced primarily by the ovaries during the reproductive years, with the granulosa cells converting androgens to estradiol via aromatase. Estrone is produced both in the ovary and, notably, through peripheral aromatization of androstenedione in adipose and other tissues. After menopause, circulating estrone increases as it continues to be produced from peripheral conversion of androstenedione, while estradiol — now derived mainly from peripheral conversion of estrone rather than ovarian synthesis — declines; this shift in relative source is part of why estrone becomes the relatively more prominent circulating estrogen after menopause.^[2] Estriol is distinctive: outside of pregnancy it is present only in small quantities, but during pregnancy the placenta produces it in large amounts, and maternal serum and urinary estriol were historically used as a marker of fetoplacental function.

Changes across reproductive life and menopause

The relative balance of the three estrogens is not static. During the reproductive years, estradiol dominates. As ovarian follicular activity declines through perimenopause and menopause, estradiol production falls substantially, and estrone — sustained by peripheral aromatization — becomes the relatively more prominent circulating estrogen, even though absolute estrogen levels overall are much lower than in the premenopausal state.^[2] Estriol, outside of pregnancy, remains a minor circulating estrogen throughout.

This shift is one reason menopausal symptoms and menopausal hormone therapy (MHT) discussions are usually framed around estradiol specifically, rather than "estrogen" as an undifferentiated category.

Receptor and tissue considerations

Estrogen effects are mediated through estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), which are expressed at different relative densities across tissues — breast, endometrium, bone, vaginal tissue, cardiovascular tissue, and the central nervous system, among others. Because the three estrogens do not necessarily bind ERα and ERβ with identical relative affinities — estrone, for example, shows notably lower binding affinity at ERβ specifically in at least one comparative study^[1] — it is biologically plausible that they could have somewhat different tissue-level effects at equivalent systemic exposure. This is an active and, in places, unsettled area of pharmacology rather than a fully resolved one.

Why the three should not be treated as interchangeable

Because estrone, estradiol and estriol differ in potency, source, and (potentially) tissue-selective effect, they are not simply interchangeable milligram-for-milligram, and the evidence base behind each is not equivalent. Most of the large, long-term outcome data that shapes menopausal hormone therapy guidance — most notably the Women's Health Initiative (WHI) hormone therapy trials — enrolled 27,347 postmenopausal women and studied conjugated equine estrogens (CEE) 0.625 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day in women with a uterus, and CEE 0.625 mg/day alone in women with a prior hysterectomy.^[3] Neither estriol nor estradiol in isolation was the estrogen studied in these WHI hormone therapy trials — a distinction worth stating precisely, since extrapolating findings from one estrogen, dose, and route to another is a reasonable starting hypothesis for clinicians to discuss, but it is not the same as having direct evidence for that specific formulation.

Compounded preparations: bi-est and tri-est

Two compounded combinations bring more than one estrogen together in a single prescription:

• Bi-est typically combines estradiol and estriol in a prescriber-specified ratio.
• Tri-est combines estrone, estradiol and estriol, again in prescriber-specified proportions.

These are patient-specific compounded preparations, not FDA-approved fixed-dose commercial drug products. The ratio, total dose, and rationale are prescribing decisions made for an individual patient — the same prescriber-directed model used across Pharmaprodia's compounding services generally. For a more detailed look at estriol specifically within these formulations, including its U.S. regulatory status, see Understanding Estriol.

Professional guidance recognizes legitimate, individualized circumstances for compounded formulations generally — for example when a needed formulation, ingredient, or route is not commercially available, or a patient has an intolerance to an ingredient in an FDA-approved product — while also noting that compounded products do not undergo the same FDA premarket review for safety, effectiveness and quality as FDA-approved medications, and that custom-compounded bioidentical formulations should not be assumed to be more effective or safer than FDA-approved options.^[4]

What the evidence does — and does not — establish

It is reasonable to say: the three estrogens are chemically related but pharmacologically distinct; estradiol is the best-studied for systemic menopausal hormone therapy; and estrone and estriol have smaller, older, or more indication-specific evidence bases (vaginal estriol for genitourinary symptoms being a notable, more established example).

It is not currently well-supported to say that any one of the three estrogens is categorically "safer" than the others across all doses, routes, and patients, or that bioidentical status alone (chemical identity to a hormone the body produces) determines a formulation's risk profile. A direct laboratory comparison of estradiol, estriol and estrone found similar cell-proliferation effects across all three in a breast-cancer cell-line model despite their receptor-binding differences^[1] — a concrete illustration that receptor potency does not, by itself, establish a safety difference. The Menopause Society and ACOG both advise that custom-compounded hormone products, including compounded estrogen combinations, should not be characterized as inherently safer or more effective than FDA-approved options.^[4][5] Bioidentical simply describes molecular structure — it does not, by itself, substitute for outcome data on a specific dose and route in a specific population.